AACR 2026: Preclinical Advances in Bispecific and Novel ADCs
At the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026, in San Diego, CA., new preclinical data will be presented for three proprietary antibody-drug conjugate (ADC) assets—CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC)—being developed by CStone Pharmaceuticals.
AACR 2026: QLS5132, a CLDN6-Targeted ADC, Demonstrates Clinical Benefit in Advanced Platinum-Resistant Ovarian Cancer
Patients treated with QLS5132, a novel antibody-drug conjugate (ADC) developed by Qilu Pharmaceutical Co. experienced clinical benefit. This conclusion is based on results from a phase 1 clinical study presented at the annual meeting of the American Association for Cancer Research, held April 17 - 22. 2026, in San Diego Ca.
Mocertatug Rezetecan Shows Promising Results in Treatment of Platinum-Resistant Ovarian and Endometrial Cancers
B7-H4 (also known as B7 homolog 4, B7S1, or VTCN1) is an immunoregulatory ligand in the B7-CD28 family, notable for its overexpression in multiple tumor types, including breast, ovarian, uterine, and lung cancers. B7-H4 suppresses T-cell effector functions, including inflammatory cytokine production and cytolytic activity, and promotes the polarisation of naïve CD4 T-cells into induced Tregs, invasion, and metastasis, correlating with poor prognosis in advanced tumors. Its restricted expression in normal tissues and tumor-promoting roles make B7-H4 an attractive target for tumor-selective therapies such as antibody-drug conjugates (ADCs). B7-H4 has attracted credible attention from drug developers because it is highly expressed in immune 'cold' tumors, in which PD-1 and PD-L1 are minimally expressed, making these tumors unresponsive to most currently used immunotherapies.
Phase 1/2 Data for JK06, a 5T4-Targeted Antibody-Drug Conjugate, Shows Promising Results
Data from a Phase 1/2 dose-escalation and expansion study of JK06, a 5T4-targeted antibody-drug conjugate (ADC) being developed by SalubrisBio, have shown promising results...
Breakthroughs in Urothelial Carcinoma: New Insights from 2026 EAU Congress on Disitamab Vedotin
Breakthroughs in Urothelial Carcinoma: New Insights from 2026 EAU Congress on Disitamab Vedotin
Preclinical Evaluation of BD200 – a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4
Antibody-drug conjugates (ADCs) have become a mainstay in targeted cancer therapies, but their effectiveness can be limited by tumor antigen heterogeneity and acquired resistance.
AACR 2026: Pioneering the Next Generation of Targeted Cancer Therapies
The landscape of cancer treatment is rapidly evolving, driven by relentless innovation and a deepening understanding of tumor biology. Among the leading developers in this revolution is Byondis, an independent Dutch biopharmaceutical company with a bold mission: to deliver breakthrough solutions for patients with cancer through the creation of innovative, targeted medicines.
AACR 2026: Conjugates Take Center Stage in Precision, Partnership, and Purpose-Driven Cancer Research
Antibody-drug conjugate (ADC) innovation continues at a remarkable pace, as evidenced by the 2026 Annual Meeting of the American Association for Cancer Research (AACR), held...
AbbVie Showcases Promising Phase 2 Data for Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer at...
AbbVie Showcases Promising Phase 2 Data for Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer at SGO 2026
The Most Interesting Activity in ADC Development is no Longer Happening in Traditional Formats
The Most Interesting Activity in ADC Development is no Longer Happening in Traditional Formats
